389 related articles for article (PubMed ID: 9532520)
1. Development of liposomal amphotericin B formulation.
Gulati M; Bajad S; Singh S; Ferdous AJ; Singh M
J Microencapsul; 1998; 15(2):137-51. PubMed ID: 9532520
[TBL] [Abstract][Full Text] [Related]
2. The novel lipid delivery system of amphotericin B: drug profile and relevance to clinical practice.
Rust DM; Jameson G
Oncol Nurs Forum; 1998; 25(1):35-48. PubMed ID: 9460772
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic and hemolytic evaluation of in-situ liposomal preparation containing amphotericin - beta complexed with different chemically modified beta - cyclodextrins.
Chakraborty KK; Naik SR
J Pharm Pharm Sci; 2003; 6(2):231-7. PubMed ID: 12935435
[TBL] [Abstract][Full Text] [Related]
4. Liposomal and lipid-based formulations of amphotericin B.
de Marie S
Leukemia; 1996 Jun; 10 Suppl 2():s93-6. PubMed ID: 8649062
[TBL] [Abstract][Full Text] [Related]
5. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
Khan MA; Owais M
J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
[TBL] [Abstract][Full Text] [Related]
6. Liposomal drug delivery system from laboratory to clinic.
Kshirsagar NA; Pandya SK; Kirodian GB; Sanath S
J Postgrad Med; 2005; 51 Suppl 1():S5-15. PubMed ID: 16519249
[TBL] [Abstract][Full Text] [Related]
7. Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS), with commercial lipid-based formulations.
Fukui H; Koike T; Nakagawa T; Saheki A; Sonoke S; Tomii Y; Seki J
Int J Pharm; 2003 Nov; 267(1-2):101-12. PubMed ID: 14602388
[TBL] [Abstract][Full Text] [Related]
8. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of the selective toxicity of amphotericin B incorporated into liposomes.
Juliano RL; Grant CW; Barber KR; Kalp MA
Mol Pharmacol; 1987 Jan; 31(1):1-11. PubMed ID: 3807887
[TBL] [Abstract][Full Text] [Related]
10. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy.
Hachem RY; Boktour MR; Hanna HA; Husni RN; Torres HA; Afif C; Kontoyiannis DP; Raad II
Cancer; 2008 Mar; 112(6):1282-7. PubMed ID: 18224662
[TBL] [Abstract][Full Text] [Related]
11. Antifungal activity of amphotericin B conjugated to carbon nanotubes.
Benincasa M; Pacor S; Wu W; Prato M; Bianco A; Gennaro R
ACS Nano; 2011 Jan; 5(1):199-208. PubMed ID: 21141979
[TBL] [Abstract][Full Text] [Related]
12. [Impact on renal function of an early switch from conventional to liposomal amphotericin B formulation in the empirical treatment of fungal infections].
Isnard F; Tilleul P; Laporte JP; Chevallier P; Pigneux A; Lafuma A; Monchecourt F; Mahi L; Deray G
Med Mal Infect; 2008 Apr; 38(4):208-14. PubMed ID: 18191521
[TBL] [Abstract][Full Text] [Related]
13. Water-soluble amphotericin B-polyvinylpyrrolidone complexes with maintained antifungal activity against Candida spp. and Aspergillus spp. and reduced haemolytic and cytotoxic effects.
Charvalos E; Tzatzarakis MN; Van Bambeke F; Tulkens PM; Tsatsakis AM; Tzanakakis GN; Mingeot-Leclercq MP
J Antimicrob Chemother; 2006 Feb; 57(2):236-44. PubMed ID: 16361329
[TBL] [Abstract][Full Text] [Related]
14. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
Shehab N; DePestel DD; Mackler ER; Collins CD; Welch K; Erba HP
Pharmacotherapy; 2007 Jul; 27(7):970-9. PubMed ID: 17594202
[TBL] [Abstract][Full Text] [Related]
15. Use of liposomal amphotericin B in bone marrow transplant.
Sastry PS; Parikh PM; Kulkarni PS; Bhagwat R; Gadade H
J Postgrad Med; 2005; 51 Suppl 1():S49-52. PubMed ID: 16519256
[TBL] [Abstract][Full Text] [Related]
16. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
[TBL] [Abstract][Full Text] [Related]
17. Liposomal amphotericin B: clinical experience and perspectives.
Gibbs WJ; Drew RH; Perfect JR
Expert Rev Anti Infect Ther; 2005 Apr; 3(2):167-81. PubMed ID: 15918775
[TBL] [Abstract][Full Text] [Related]
18. Use of high-dose liposomal amphotericin B: efficacy and tolerance.
Garbino J; Adam A
Acta Biomed; 2006; 77 Suppl 4():19-22. PubMed ID: 17370566
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation.
Gershkovich P; Wasan EK; Lin M; Sivak O; Leon CG; Clement JG; Wasan KM
J Antimicrob Chemother; 2009 Jul; 64(1):101-8. PubMed ID: 19398459
[TBL] [Abstract][Full Text] [Related]
20. Incorporation of amphotericin B (AMB) into liposomes alters AMB-induced acute nephrotoxicity in rabbits.
Joly V; Dromer F; Barge J; Yeni P; Seta N; Molas G; Carbon C
J Pharmacol Exp Ther; 1989 Oct; 251(1):311-6. PubMed ID: 2795463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]